Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Fattori di patogenicità dello Staphylococcus Pettenkoferi nelle ferite del piede e nell'osteite nei pazienti diabetici (PETTENK-OS)

22 settembre 2026 aggiornato da: Centre Hospitalier Universitaire de Nīmes

Valutazione dei fattori di patogenicità dello Staphylococcus Pettenkoferi nelle ferite del piede e nell'osteite nei pazienti diabetici. Lo studio PETTENK-OS

Gram-positive cocci, particularly Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. Although studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no studies have focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is unknown, yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory and 80% of the bacteria present are in biofilms.It is essential to understand the mechanisms governing these bacterial interactions and establish the true pathogenic potential of these bacteria. Recently, the Nîmes team showed that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. SP165 could not only produce biofilm, but could also survive in human blood, human keratinocytes and murine and human macrophages. It also caused significant embryonic mortality in a zebrafish model. A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated that there were two predominant clones with different virulences. Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.

Panoramica dello studio

Descrizione dettagliata

Gram-positive cocci, in particular Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. While studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no study has focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is not known. Yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. In the work of Loetsche et al. a study of the microbiome of 349 diabetic foot ulcer samples by targeted 16S rDNA sequencing showed that the genus Staphylococcus was the most abundant, with a relative abundance of 22.8%, including 13.3% S. aureus and 5.3% S. pettenkoferi.

At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory (89 isolations of S. pettenkoferi from diabetic foot ulcer samples out of 167 isolations made of this bacterium between 2018 and 2022).The difficulty of managing chronic wounds also lies in the fact that almost 80% of the bacteria present are in biofilms. It has also been established that the environment in which bacteria are found, and in particular the interactions they establish between themselves, play a significant role in delayed wound healing. It is therefore essential to understand the mechanisms governing these bacterial interactions and to establish the true pathogenic potential of these bacteria.

Recently, our team demonstrated that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. As well as being able to produce biofilm, SP165 was able to survive in human blood, human keratinocytes and murine and human macrophages. It also demonstrated its virulence by causing significant embryonic mortality in the zebrafish model.

A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated the existence of two predominant clones with different virulences.

Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish virulence profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.

Tipo di studio

Osservativo

Iscrizione (Effettivo)

230

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Gard
      • Nîmes, Gard, Francia, 30029
        • Nîmes University Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The collection of strains at the Nîmes University Hospital site from 9 European laboratories collected between 2015 and 2023 for a total of 108 months was carried out between November 2021 and August 2023.

Descrizione

Inclusion Criteria:

  • Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi

Exclusion Criteria:

  • Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: OTHER

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Genetic diversity of Staphyloccocus pettenkoferi strains isolated from osteitis and non-diabetic wounds, blood cultures and nasal carriage.
Lasso di tempo: Day 0 to 3 months

Number of clades estimated via typing by complete sequencing of the bacterial genomes of all S. pettenkoferi strains and analysis of phylogenetic distances (whole genome and core genome single nucleotide polymorphisms).

Day 0 to 3 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Genetic diversity of Staphyloccocus pettenkoferi strains isolated from osteitis and non-diabetic wounds, blood cultures and nasal carriage.
Lasso di tempo: 3 - 6 months

Number of clades estimated via typing by complete sequencing of the bacterial genomes of all Staphylococcus pettenkoferi strains and analysis of phylogenetic distances.

3 - 6 months
Resistome in the strain population according to sample origin:osteitis
Lasso di tempo: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Resistome in the strain population according to sample origin: non-diabetic wounds
Lasso di tempo: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Resistome in the strain population according to sample origin: diabetic wounds
Lasso di tempo: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Resistome in the strain population according to sample origin: blood cultures
Lasso di tempo: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Resistome in the strain population according to sample origin: nasal carriage
Lasso di tempo: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: osteitis
Lasso di tempo: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: non-diabetic wounds
Lasso di tempo: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: diabetic wounds
Lasso di tempo: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: blood cultures
Lasso di tempo: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: nasal carriage
Lasso di tempo: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: osteitis
Lasso di tempo: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: non-diabetic wounds
Lasso di tempo: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: diabetic wounds
Lasso di tempo: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: blood cultures
Lasso di tempo: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: nasal carriage
Lasso di tempo: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Phenotypic resistance profiles in the population in a subsample of 85 strains
Lasso di tempo: 6 - 14 months

The minimum inhibitory concentration for a series of antibiotics will be recorded (antibiograms of isolates).These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: osteitis
Lasso di tempo: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: non-diabetic wounds
Lasso di tempo: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: diabetic wounds
Lasso di tempo: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: blood cultures
Lasso di tempo: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: nasal carriage
Lasso di tempo: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: osteitis
Lasso di tempo: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: non-diabetic wounds
Lasso di tempo: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: diabetic wounds
Lasso di tempo: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: blood cultures
Lasso di tempo: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: nasal carriage
Lasso di tempo: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: osteitis
Lasso di tempo: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: non-diabetic wounds
Lasso di tempo: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: diabetic wounds
Lasso di tempo: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: blood cultures
Lasso di tempo: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: nasal carriage
Lasso di tempo: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: osteitis
Lasso di tempo: 6 - 14 months

The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1)

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: intracellular bacterial multiplication of S. pettenkoferi strains from osteitis
Lasso di tempo: 6 - 14 months

The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7).

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: diabetic wounds
Lasso di tempo: 6 - 14 months

The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1)

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: intracellular bacterial multiplication of S. pettenkoferi strains from diabetic wounds
Lasso di tempo: 6 - 14 months

The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7).

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: blood cultures
Lasso di tempo: 6 - 14 months

The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1)

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains:intracellular bacterial multiplication of S. pettenkoferi strains from blood cultures
Lasso di tempo: 6 - 14 months

The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7).

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: nasal carriage
Lasso di tempo: 6 - 14 months

The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1)

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains:intracellular bacterial multiplication of S. pettenkoferi strains from nasal carriage
Lasso di tempo: 6 - 14 months

The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7).

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from osteitis
Lasso di tempo: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from non-diabetic wounds
Lasso di tempo: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from diabetic wounds
Lasso di tempo: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from blood cultures
Lasso di tempo: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from nasal carriage
Lasso di tempo: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 gennaio 2024

Completamento primario (Effettivo)

31 dicembre 2025

Completamento dello studio (Effettivo)

31 dicembre 2025

Date di iscrizione allo studio

Primo inviato

9 novembre 2024

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2024

Primo Inserito (Effettivo)

14 novembre 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

25 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

22 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi